Q2 Earnings Forecast for CAPR Issued By HC Wainwright

Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) - Investment analysts at HC Wainwright issued their Q2 2025 earnings estimates for Capricor Therapeutics in a research note issued on Thursday, March 20th. HC Wainwright analyst J. Pantginis anticipates that the biotechnology company will post earnings of ($0.36) per share for the quarter. HC Wainwright has a "Buy" rating and a $77.00 price target on the stock. The consensus estimate for Capricor Therapeutics' current full-year earnings is ($1.21) per share.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last issued its quarterly earnings data on Wednesday, March 19th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.31) by $0.15. The company had revenue of $11.13 million for the quarter, compared to the consensus estimate of $9.87 million. Capricor Therapeutics had a negative return on equity of 112.95% and a negative net margin of 146.86%.

Separately, Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $30.00 target price on shares of Capricor Therapeutics in a research note on Thursday, March 20th. One analyst has rated the stock with a sell rating and six have issued a buy rating to the company's stock. Based on data from MarketBeat, Capricor Therapeutics presently has an average rating of "Moderate Buy" and an average target price of $34.50.

Remove Ads

Capricor Therapeutics Trading Up 1.5 %

Shares of CAPR traded up $0.20 during trading hours on Friday, reaching $13.48. 813,937 shares of the company's stock traded hands, compared to its average volume of 1,390,196. Capricor Therapeutics has a 12 month low of $3.52 and a 12 month high of $23.40. The stock has a market cap of $612.94 million, a PE ratio of -12.72 and a beta of 4.10. The firm's 50 day simple moving average is $14.09 and its 200-day simple moving average is $14.83.

Hedge Funds Weigh In On Capricor Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Magnus Financial Group LLC bought a new stake in Capricor Therapeutics during the 4th quarter valued at $276,000. State Street Corp increased its position in shares of Capricor Therapeutics by 27.8% in the third quarter. State Street Corp now owns 512,313 shares of the biotechnology company's stock valued at $7,792,000 after acquiring an additional 111,291 shares during the period. JPMorgan Chase & Co. raised its stake in shares of Capricor Therapeutics by 419.5% during the third quarter. JPMorgan Chase & Co. now owns 56,199 shares of the biotechnology company's stock valued at $855,000 after acquiring an additional 45,381 shares during the last quarter. Point72 Asset Management L.P. bought a new position in shares of Capricor Therapeutics during the third quarter valued at about $3,806,000. Finally, Black Diamond Financial LLC purchased a new stake in shares of Capricor Therapeutics during the fourth quarter worth about $3,833,000. 21.68% of the stock is currently owned by institutional investors.

About Capricor Therapeutics

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.